Southwest Securities released a research report on April 24 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the domestic market share of cyclopofol is 11%, and it is expected that NDA will be declared in the US in 2024; 2) HSK16149 capsules are expected to be approved for marketing in 2024Q2; 3) the HSK21542 injection application has been accepted, and the oral dosage form has entered Phase II clinical trials; 4) the innovation pipeline is progressing rapidly, and potential varieties such as NASH and PROTAC are worth looking forward to. (Mainichi Keizai Shimbun)
西南证券4月24日发布研报称，给予海思科（002653.SZ）买入评级。评级理由主要包括：1）环泊酚国内静脉麻醉市占率达11%，2024年有望在美国申报NDA；2）HSK16149胶囊有望2024Q2获批上市；3）HSK21542注射液上市申请获受理，口服剂型进入二期临床；4）创新管线快速推进，NASH、PROTAC等潜力品种值得期待。（每日经济新闻）
Southwest Securities released a research report on April 24 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the domestic market share of cyclopofol is 11%, and it is expected that NDA will be declare
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.